SGLT2 inhibitors compared with other glucose ‐lowering drugs in Japan: Subanalyses of the CVD‐REAL 2 Study

In conclusion, SGLT2i initiators had lower risks of CV events versus oGLD initiators and, uniquely, versus DPP4i initiators in Japanese real‐world practice.

Source: Journal of Diabetes Investigation - June 11, 2020 Category: Endocrinology Authors: Shun Kohsaka, Masayoshi Takeda, Johan Bodegard, Marcus Thuresson, Mikhail Kosiborod, Toshitaka Yajima, Eric Wittbrodt, Peter Fenici Tags: SHORT REPORT Source Type: research